Targeted cancer therapies (biologics)

Vidhi Desai, Jyotsana Thakkar, Rimda Wanchoo, Kenar D. Jhaveri

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Novel targeted anticancer therapies have resulted in improvement in patient survival compared with standard chemotherapy. Renal toxicities of targeted agents are increasingly being recognized. The incidence, severity, and pattern of renal toxicities may vary according to the respective target of the drug. In this chapter, we review the adverse renal effects associated with a selection of currently approved targeted cancer therapies, directed to epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER 2), v-RAF murine sarcoma viral oncogene homolog B (BRAF), mitogen-activated protein kinases (MEK), anaplastic lymphoma kinase (ALK), and agents targeted to vascular endothelial growth factor receptor (VEGF/R) and tyrosine kinase inhibitors (TKIs). In summary, electrolyte disorders, renal impairment and hypertension are the most commonly reported events. The early diagnosis and prompt recognition of these renal adverse events are essential for the general nephrologist taking care of these patients.

Original languageEnglish (US)
Title of host publicationOnco-Nephrology
PublisherElsevier
Pages154-165.e4
ISBN (Electronic)9780323549455
ISBN (Print)9780323549615
DOIs
StatePublished - Jan 1 2019

Keywords

  • AKI
  • Electrolyte disorders
  • TMA
  • Targeted therapies

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Targeted cancer therapies (biologics)'. Together they form a unique fingerprint.

Cite this